Harmonic Discovery Inc. has entered into an exclusive licensing agreement for a small-molecule drug candidate for the treatment of FLT3-mutated acute myeloid leukemia (AML) from Bioventures (University of Arkansas for Medical Sciences) and University of California San Francisco (UCSF).
The activation of PERK signaling triggers angiogenesis, migration and dissemination of cancer cells, and for that reason, the therapeutic blockade of the PERK pathway is a target to watch in cancer therapy. Researchers from Chongqing Medical University reported on the preclinical efficacy and molecular mechanism of CCT-020312, a selective PERK activator, in prostate cancer models.
CAR T cells could be repurposed to target senescent cells and delay the effect of aging. A study by scientists at Cold Spring Harbor Laboratory showed how to design them and demonstrated the advantages of this therapy in mice. “We only gave one dose, and we could have benefits [for] really long periods of time,” lead author Corina Amor told BioWorld.
2seventy bio Inc. shares (NASDAQ:TSVT) rose 15% or 52 cents, to close Jan. 30 at $4.01 on word that the Cambridge, Mass.-based firm is selling its R&D pipeline to Regeneron Pharmaceuticals Inc., which will move the work forward by way of a new company called Regeneron Cell Medicines.
Institute of Cancer Research UK has described lysyl oxidase homolog 2 (LOXL2) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Dana-Farber Cancer Institute Inc. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase ligand binding moiety covalently linked to an histone deacetylase 6 (HDAC6)/8 (HDAC8)-targeting moiety through a linker.
Zentaur Therapeutics USA Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Transcode Therapeutics Inc. has entered into a co-research agreement with Debiopharm SA that will bring together Transcode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer.
Researchers from Shanghai Xianhui Pharmaceutical Co. Ltd. have detailed the discovery and preclinical characterization of novel photosensitizers as candidates for photodynamic therapy (PDT) and photodiagnosis in cancer.
Hookipa Pharma Inc.’s nearly $1 billion collaboration with Roche Holding AG dissolved along with 30% of the company’s staff. The New York-based company said Roche ended the October 2022 deal involving the HB-700 program in treating KRAS mutated cancers but did not say why the agreement fell apart. Leerink Partners analyst Andrew Berens wrote Jan. 29 that the firm spoke to management, which indicated the program was progressing according to plan and that Roche's decision was based more on its own internal pipeline strategy, lessening its focus on oncology after high profile failures vs. the program having issues in development.
RSS
